As per a new industry analysis by Fact.MR, a market research and competitive intelligence provider, the global optical preclinical imaging market is valued at US$ 612 million in 2023. Global sales of optical preclinical imaging devices are predicted to increase at a CAGR of 6.5% from 2023 to 2033.
In animal studies for the development of drugs, optical preclinical imaging technologies are employed. Monitoring the therapy response for early signs of efficacy also involves optical preclinical imaging. In-vivo imaging technology advancements give researchers a chance to quantitatively examine disease at the molecular level. With the use of in-vivo imaging, preclinical studies on animal models may be quickly and directly applied to clinical research in humans. This bridges the gap between in-vitro exploratory and in-vivo clinical research. In-vivo preclinical imaging is mostly used to treat diseases related to cancer, autoimmune disorders, neurological conditions, and cardiovascular problems.
The introduction of several fresh and technologically sophisticated medical equipment, medical imaging devices, and pharmaceutical & biopharmaceutical goods shows that the healthcare business is growing healthily, despite the extreme political and economic uncertainties happening across the world. Preclinical imaging and new variations of in-vivo preclinical imaging have been developed to evaluate new methods for revealing disease genesis, disease progression, and metastasis & progression of cancers.
Download a Free Sample Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=8379
North America currently dominates the global market due to the presence of well-established pharma and biotech industries. With the existence of the most prominent research facilities and medicine manufacturing sector, demand for optical preclinical imaging devices is increasing rapidly in Europe.
Key Takeaways from Market Study
- The global optical preclinical imaging devices market is expected to reach US$ 1.14 billion by the year 2033.
- The market in China is predicted to expand at a massive CAGR of 10% during the projected period.
- Demand for bioluminescence/fluorescence imaging systems is expected to rise at a CAGR of 7.5% during the next 10 years.
- Sales of optical preclinical imaging solutions in Canada are anticipated to evolve at a 4.5% CAGR during the forecast period.
“Rising prevalence of chronic disorders & infectious diseases across the world are boosting the demand for optical preclinical imaging solutions,” says a Fact.MR analyst.
Key Segments of Optical Preclinical Imaging Industry Research
- By Modality :
- Bioluminescence/Fluorescence Imaging Systems
- Standalone Fluorescence Imaging Systems
- Optical + X-ray/Optical + CT
- By Reagent :
- Bioluminescent Imaging Reagents
- Fluorescent Imaging Reagents
- By Application :
- Research & Development
- Drug Discovery
- By End User :
- Pharma & Biotech Companies
- Research Institutes
- By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Get Customization on this Report for Specific Research Solutions - https://www.factmr.com/connectus/sample?flag=RC&rep_id=8379
Key Market Developments
- The Velocity MRI System was introduced by Fujifilm in November 2021 at the Radiological Society of North America (RSNA) meeting. Using cutting-edge technologies, open MRI's clinical and comfort advantages are combined with a high-performance and high-field scanner.
- Kawasaki Medical University, a research hub for cutting-edge medical services and technology in Yokohama, Japan, established the country's first ultra-high resolution E-class system for preclinical imaging in 2019.
Key Companies Profiled
- BioTek Instruments, Inc.
- Bruker Corporation
- Fujifilm Holdings Corporation
- Magnetic Insight, Inc.
- MBF Bioscience
- Mediso Ltd.
- MILabs B.V.
- Miltenyi Biotec
- MR Solutions
- PerkinElmer, Inc.
- TriFoil Imaging
- Vieworks Co., Ltd.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global optical preclinical imaging market, presenting historical demand data (2018 to 2022) and forecast statistics for the period of 2023 to 2033.
The study divulges essential insights into the market on the basis of modality (bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems, optical + X-ray/optical + CT), reagent (bioluminescent imaging reagents, fluorescent imaging reagents), application (research & development, drug discovery), and end user (pharma & biotech companies, research institutes), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
